India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.

Bio Farma says new technology will help expand vaccines production and work on a hepatitis B vaccine as the country moves to launch a phased universal health care insurance program next year.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.